Filtered By:
Cancer: Liver Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1432 results found since Jan 2013.

5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
In conclusion, our findings suggest that 3p-siRNA could act as a powerful bifunctional antiviral molecule with potential for developing a promising therapeutic against chronic HBV infection. PMID: 24099962 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - October 4, 2013 Category: Drugs & Pharmacology Authors: Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z Tags: Eur J Pharmacol Source Type: research

Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
In conclusion, TPGS-coated cationic liposomes with Bcl-2 siRNA corona had the capacity to inhibit MDR dual-pathways and subsequently improved the anti-tumor activity of the chemotherapeutic agent co-delivered to a level that cannot be achieved by inhibiting a MDR single way.Graphical abstract
Source: Asian Journal of Pharmaceutical Sciences - November 13, 2019 Category: Drugs & Pharmacology Source Type: research

Molecules, Vol. 28, Pages 2191: Potential of siRNA-Bearing Subtilosomes in the Treatment of Diethylnitrosamine-Induced Hepatocellular Carcinoma
grawal Mohammad Owais Therapeutics, based on small interfering RNA (siRNA), have demonstrated tremendous potential for treating cancer. However, issues such as non-specific targeting, premature degradation, and the intrinsic toxicity of the siRNA, have to be solved before they are ready for use in translational medicines. To address these challenges, nanotechnology-based tools might help to shield siRNA and ensure its specific delivery to the target site. Besides playing a crucial role in prostaglandin synthesis, the cyclo-oxygenase-2 (COX-2) enzyme has been reported to mediate carcinogenesis in various types of canc...
Source: Molecules - February 27, 2023 Category: Chemistry Authors: Fauzia Jamal Ghufran Ahmed Mohammad Farazuddin Ishrat Altaf Saba Farheen Qamar Zia Asim Azhar Hira Ahmad Aijaz Ahmed Khan Satyanarayana Somavarapu Anshu Agrawal Mohammad Owais Tags: Article Source Type: research

Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice
Conclusions: EMF-guided 131I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of 131I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional properties of tumor therapy and imaging.
Source: BMC Cancer - February 21, 2014 Category: Cancer & Oncology Authors: Jing ChenShu ZhuLiangqian TongJiansha LiFei ChenYunfeng HanMing ZhaoWei Xiong Source Type: research

Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Abstract Drug resistance is a big problem in systemic chemotherapy of hepatocellular carcinoma (HCC), and nanomedicines loaded with both chemotherapeutic agents (e.g. paclitaxel, PTX) and siRNA's targeting antiapoptosis genes (e.g. BCL-2) possess the advantages to simultaneously overcome the efflux pump-mediated drug resistance and antiapoptosis-related drug resistance. However, tumor-penetrating drug delivery with this type of nanomedicines is extremely difficult due to their relatively big size compared to the single drug-loaded nanomedicines. Aiming at address this problem, US-responsive nanobubbles encapsulati...
Source: Biomaterials - April 17, 2014 Category: Materials Science Authors: Yin T, Wang P, Li J, Wang Y, Zheng B, Zheng R, Cheng D, Shuai X Tags: Biomaterials Source Type: research

Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells
Conclusion MixNCH/MK-siRNA nanoparticles could be effective for the treatment of hepatocellular carcinoma.
Source: Hepatobiliary and Pancreatic Diseases International - February 14, 2015 Category: Gastroenterology Source Type: research

Development of a simple, biocompatible and cost-effective Inulin- Diethylenetriamine based siRNA delivery system.
In conclusion, we developed a novel inulin-based siRNA delivery system able to efficiently release siRNA in JHH6 with negligible cytotoxicity thus opening the way for further testing in more complex in vivo models. PMID: 25845631 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - April 3, 2015 Category: Drugs & Pharmacology Authors: Sardo C, Farra R, Licciardi M, Dapas B, Scialabba C, Giammona G, Grassi M, Grassi G, Cavallaro G Tags: Eur J Pharm Sci Source Type: research

Effect of siRNA on Wisp-1 gene expression, proliferation, migration and adhesion of mouse hepatocellular carcinoma cells
Conclusions The inhibition of Wisp-1 expression can reduce the proliferation, migration and adhesion of mouse hepatocellular carcinoma cells, which is related to the AKT/glycogen synthase kinase-3β pathway. Wisp-1 gene may be the potential target to cure the hepatocellular carcinoma.
Source: Asian Pacific Journal of Tropical Medicine - October 4, 2015 Category: Tropical Medicine Source Type: research

Hydroxyapatite nanoparticles modified by branched polyethylenimine are effective non-viral vectors for siRNA transfection of hepatoma cells in vitro.
Abstract Small interfering RNA (siRNA) technology is a powerful tool in biomedical research and holds great potential for RNA interference-based therapies for HIV, hepatitis and cancer. However, the absence of a safe and efficient method for the delivery of siRNA has become a bottleneck for their development. Nanocrystallized hydroxyapatite (nHAP) appears to be an optimal candidate non-viral gene vector for several reasons, including its good biocompatibility and ease of production, however, nHAP microemulsions cannot remain monodispersed for long periods of time. Due to their high surface energy, nHAP particles g...
Source: International Journal of Oncology - March 5, 2015 Category: Cancer & Oncology Authors: Xu XL, Yang HY, Ou B, Lin SD, Wu H, He W, Jiang QC, Luo BM, Li GP Tags: Int J Oncol Source Type: research

Iron‐Oxide‐Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence‐specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle‐based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP‐siRNA‐GPC3 Ab) is made of an iron oxide core coated with chitosan‐polyet...
Source: Small - December 1, 2015 Category: Nanotechnology Authors: Kui Wang, Forrest M. Kievit, Jonathan G. Sham, Mike Jeon, Zachary R. Stephen, Arvind Bakthavatsalam, James O. Park, Miqin Zhang Tags: Full Paper Source Type: research

Pharmacokinetics and Biodistribution of Recently-Developed siRNA Nanomedicines.
Abstract Small interfering RNA (siRNA) is a promising drug candidate, expected to have broad therapeutic potentials toward various diseases including viral infections and cancer. With recent advances in bioconjugate chemistry and carrier technology, several siRNA-based drugs have advanced to clinical trials. However, most cases address local applications or diseases in the filtering organs, reflecting remaining challenges in systemic delivery of siRNA. The difficulty in siRNA delivery is in large part due to poor circulation stability and unfavorable pharmacokinetics and biodistribution profiles of siRNA. This rev...
Source: Advanced Drug Delivery Reviews - December 10, 2015 Category: Drugs & Pharmacology Authors: Park J, Park J, Pei Y, Xu J, Yeo Y Tags: Adv Drug Deliv Rev Source Type: research

Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Abstract The chemotherapy combined with gene therapy has received great attention. We developed targeted LPD (liposome-polycation-DNA complex) conjugated with anti-EGFR (epidermal growth factor receptor) Fab' co-delivering adriamycin (ADR) and ribonucleotide reductase M2 (RRM2) siRNA (ADR-RRM2-TLPD), to achieve combined therapeutic effects in human hepatocellular carcinoma (HCC) overexpressing EGFR. The antitumor activity and mechanisms of ADR-RRM2-TLPD were investigated. The results showed that RRM2 expression was higher in HCC than in non-HCC tissue, and RRM2 siRNA inhibited HCC cell proliferation, suggesting th...
Source: Biomaterials - September 20, 2013 Category: Materials Science Authors: Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H, Dai J, Guo Y Tags: Biomaterials Source Type: research

Enhanced antitumor efficacies of multifunctional nanocomplexes through knocking down the barriers for siRNA delivery.
Abstract Multifunctional nanocomplexes (NCs) consisting of urocanic acid-modified galactosylated trimethyl chitosan (UA-GT) conjugates as polymeric vectors, poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit) as charge-reversible crosslinkers, and vascular endothelial growth factor (VEGF) siRNA as therapeutic genes, were rationally designed to simultaneously overcome the extracellular, cellular, and intracellular barriers for siRNA delivery. The strong physical stability of UA-GT/PAH-Cit/siRNA NCs (UA-GT NCs) at pH 7.4 and 6.5 endowed protection from massive dilution, competitive ions, and ubiquitous nuc...
Source: Biomaterials - February 1, 2015 Category: Materials Science Authors: Han L, Tang C, Yin C Tags: Biomaterials Source Type: research

siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.
Abstract Activatable cell-penetrating peptides (aCPPs) allow nonviral, low cytotoxic, and selective delivery of compounds into target cells for cancer therapy. In tumor cells, up-regulation of human telomerase reverse transcriptase (hTERT) frequently occurs and is being considered as a target in cancer diagnosis and treatment. siRNA sequence that target hTERT mRNA can silence the gene and reduce hTERT protein expression to reduce cell proliferation and inhibit cell growth. In our study, we tested a matrix metalloproteinase-2 (MPP2) activatable cell-penetrating peptide (CPP) in delivering hTERT siRNA into SMMC-7721...
Source: Bioscience Reports - February 11, 2015 Category: Biomedical Science Authors: Li H, He J, Yi H, Xiang G, Chen K, Fu B, Yang Y, Chen G Tags: Biosci Rep Source Type: research

Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
In this study, we assembled lipid/calcium/phosphate nanoparticles (LCP NPs) conjugated with eight types of galactoside derivatives and demonstrated that phenyl β-d-galactoside-decorated LCP NPs (L4-LCP NPs) exhibited a superior siRNA delivery into HCC cells compared to normal hepatocytes. VEGF siRNAs delivered by L4-LCP NPs downregulated VEGF expression in HCC in vitro and in vivo and led to a potent antiangiogenic effect in the tumor microenvironment of a murine orthotopic HCC model. The efficient delivery of VEGF siRNA by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be...
Source: Biomacromolecules - May 29, 2018 Category: Biochemistry Authors: Huang KW, Lai YT, Chern GJ, Huang SF, Tsai CL, Sung YC, Chiang CC, Hwang PB, Ho TL, Huang RL, Shiue TY, Chen Y, Wang SK Tags: Biomacromolecules Source Type: research